Market Research Logo

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides an overview of the Metastatic Ovarian Cancer (Oncology) pipeline landscape.

Metastatic ovarian cancer is a type of cancer that originates in the ovaries, but then spreads to other areas of the body, such as the diaphragm, intestine, mentum (a fatty layer that covers and pads abdominal organs), liver or lungs. Symptoms include fatigue, getting full quickly, abdominal swelling, leg swelling, changes in bowel habits, and changes in bladder habits, abdominal pain, and shortness of breath. Metastatic ovarian cancer is often treated with a combination of therapies that can include surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Metastatic Ovarian Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Metastatic Ovarian Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Metastatic Ovarian Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 9 and 2 respectively for Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively for Metastatic Ovarian Cancer.

Metastatic Ovarian Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Metastatic Ovarian Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Metastatic Ovarian Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Metastatic Ovarian Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Metastatic Ovarian Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Metastatic Ovarian Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Metastatic Ovarian Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Metastatic Ovarian Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Metastatic Ovarian Cancer Overview
Therapeutics Development
Pipeline Products for Metastatic Ovarian Cancer - Overview
Pipeline Products for Metastatic Ovarian Cancer - Comparative Analysis
Metastatic Ovarian Cancer - Therapeutics under Development by Companies
Metastatic Ovarian Cancer - Therapeutics under Investigation by Universities/Institutes
Metastatic Ovarian Cancer - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Metastatic Ovarian Cancer - Products under Development by Companies
Metastatic Ovarian Cancer - Products under Investigation by Universities/Institutes
Metastatic Ovarian Cancer - Companies Involved in Therapeutics Development
Adgero Biopharmaceuticals Inc
Cellceutix Corporation
Eisai Co., Ltd.
F. Hoffmann-La Roche Ltd.
Immune Design Corp.
Millennium Pharmaceuticals Inc
MolMed S.p.A.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Pfizer Inc.
Richter Gedeon Nyrt.
Sumitomo Dainippon Pharma Co., Ltd.
VG Life Sciences, Inc.
Metastatic Ovarian Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Antisense RNAi Oligonucleotide to Replace MicroRNA-138 for Metastatic Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevacizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CMB-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCVax-Direct - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DCVax-L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-7449 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emactuzumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gedatolisib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hydroxychloroquine + sorafenib tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kevetrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LV-305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NGR-hTNF - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NRCAN-019 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
orteronel - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OS-2966 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REM-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SM-276001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metastatic Ovarian Cancer - Dormant Projects
Metastatic Ovarian Cancer - Discontinued Products
Metastatic Ovarian Cancer - Product Development Milestones
Featured News & Press Releases
Jun 22, 2015: VG Life Sciences Granted Combination Cancer Drug Patent
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Metastatic Ovarian Cancer - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016
Metastatic Ovarian Cancer - Pipeline by Cellceutix Corporation, H2 2016
Metastatic Ovarian Cancer - Pipeline by Eisai Co., Ltd., H2 2016
Metastatic Ovarian Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
Metastatic Ovarian Cancer - Pipeline by Immune Design Corp., H2 2016
Metastatic Ovarian Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
Metastatic Ovarian Cancer - Pipeline by MolMed S.p.A., H2 2016
Metastatic Ovarian Cancer - Pipeline by Natco Pharma Limited, H2 2016
Metastatic Ovarian Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2016
Metastatic Ovarian Cancer - Pipeline by Pfizer Inc., H2 2016
Metastatic Ovarian Cancer - Pipeline by Richter Gedeon Nyrt., H2 2016
Metastatic Ovarian Cancer - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Metastatic Ovarian Cancer - Pipeline by VG Life Sciences, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Metastatic Ovarian Cancer - Dormant Projects, H2 2016
Metastatic Ovarian Cancer - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Metastatic Ovarian Cancer, H2 2016
Number of Products under Development for Metastatic Ovarian Cancer - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report